Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Personalized Therapy and Clinical Outcome for Heart Valves
share announcement

Personalized Therapy and Clinical Outcome for Heart Valves

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 1579

Special Issue Editors

Dr. Erez Sharoni

E-Mail Website
Guest Editor
Carmel Medical Center, Mikhal St 7, Haifa 3436212, Israel
Interests: cardiothoracic surgery; valve repair; beating heart surgery; surgical solutions for CHF
Dr. Guy Witberg

E-Mail Website
Guest Editor
Department of Cardiology, Rabin Medical Center, Petah Tikva 4941492, Israel
Interests: myocarditis; congenital heart disease; percutaneous coronary intervention; transcatheter aortic valve replacement
Dr. Dror B. Leviner

E-Mail Website
Guest Editor
Department of Cardiac Surgery, Carmel Medical Center, Haifa 34361, Israel
Interests: coronary artery bypass graft; aortic valve replacement; mitral valve replacement; mitral valve repair
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

With advanced medical technology, the treatment of heart valves has revolutionized. A range of innovative, minimally invasive procedures have been developed, such as transcatheter aortic valve replacement (TAVR), anticoagulation management, minimally invasive procedures, imaging technologies, percutaneous mitral valve repair (MitraClip) and robotic mitral valve repair. New techniques have improved the survival and quality of life of formerly untreatable patients. But there are still some challenges that require clinicians and researchers to continue and promote the clinical management of heart valves.

The primary goals of this Special Issue are to improve the personalized therapy and clinical outcomes for those with heart valve problems. We look forward to your enthusiastic participation in this Special Issue that will promote scientific communication, with the ultimate goal of positively influencing the treatment and care of patients.

Dr. Erez Sharoni
Dr. Guy Witberg
Dr. Dror B. Leviner
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • interventional cardiology
  • tricuspid valve (TV) disease
  • heart valves
  • antithrombotic therapy
  • aortic valve implan-tation
  • bicuspid aortic valve

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 2115 KiB  
Article
Outcomes of Mitral Valve Regurgitation Management after Expert Multidisciplinary Valve Team Evaluation
by Myrthe J. M. Welman, Sebastian A. F. Streukens, Anass Mephtah, Loes P. Hoebers, Jindrich Vainer, Ralph Theunissen, Samuel Heuts, Jos G. Maessen, Patrique Segers, Kevin Vernooy, Arnoud W. J. van ‘t Hof, Peyman Sardari Nia and Pieter A. Vriesendorp
J. Clin. Med. 2024, 13(15), 4487; https://doi.org/10.3390/jcm13154487 - 31 Jul 2024
Viewed by 380
Abstract
Background/Objectives: Mitral regurgitation (MR) affects millions worldwide, necessitating timely intervention. There are significant clinical challenges in the conservative management of MR, leaving a knowledge gap regarding the impact of multidisciplinary decision-making on treatment outcomes. This study aimed to provide insights into the [...] Read more.
Background/Objectives: Mitral regurgitation (MR) affects millions worldwide, necessitating timely intervention. There are significant clinical challenges in the conservative management of MR, leaving a knowledge gap regarding the impact of multidisciplinary decision-making on treatment outcomes. This study aimed to provide insights into the impact of multidisciplinary decision-making on the survival outcomes of MR patients, focusing on conservative approaches. Methods: This study retrospectively analyzes 1365 patients evaluated by an expert multidisciplinary heart team (MDT) in a single center from 2015 to 2022. Treatments included surgery, catheter-based interventions, and conservative management. Propensity matching was utilized to compare surgery and conservative approaches. Results: Surgical intervention was associated with superior long-term survival outcomes compared to conservative and catheter-based treatments, particularly for degenerative MR (DMR). Survival rates of patients deemed by the MDT to have non-severe DMR were comparable to surgical patients (HR 1.07, 95% CI: 0.37–3.12, p = 0.90). However, non-severe functional MR (FMR) patients trended towards elevated mortality risk (HR 1.77, 95% CI: 0.94–3.31, p = 0.07). Pharmacological treatment for DMR was associated with significantly higher mortality compared to surgery (HR 8.0, 95% CI: 1.78–36.03, p = 0.001). Functional MR patients treated pharmacologically exhibited a non-significantly higher mortality risk compared to surgical intervention (HR 1.93, 95% CI: 0.77–4.77, p = 0.20). Conclusions: Survival analysis revealed significant benefits for surgical intervention, contrasting with elevated mortality risks associated with conservative management. “Watchful waiting” may be appropriate for non-severe DMR, while FMR may require closer monitoring. Further research is needed to assess the impact of regular follow-up or delayed surgery on survival rates, as pharmacological therapy has limited long-term efficacy for DMR. Full article
(This article belongs to the Special Issue Personalized Therapy and Clinical Outcome for Heart Valves)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 1335 KiB  
Review
Mechanical Valves: Past, Present, and Future—A Review
by Dror B. Leviner, Dana Abraham, Tom Ronai and Erez Sharoni
J. Clin. Med. 2024, 13(13), 3768; https://doi.org/10.3390/jcm13133768 - 27 Jun 2024
Viewed by 859
Abstract
The mechanical valve was first invented in the 1950s, and since then, a wide variety of prostheses have been developed. Although mechanical valves have outstanding durability, their use necessitates life-long treatment with anticoagulants, which increases the risk of bleeding and thromboembolic events. The [...] Read more.
The mechanical valve was first invented in the 1950s, and since then, a wide variety of prostheses have been developed. Although mechanical valves have outstanding durability, their use necessitates life-long treatment with anticoagulants, which increases the risk of bleeding and thromboembolic events. The current guidelines recommend a mechanical prosthetic valve in patients under 50–60 years; however, for patients aged 50–70 years, the data are conflicting and there is not a clear-cut recommendation. In recent decades, progress has been made in several areas. First, the On-X mechanical valve was introduced; this valve has a lower anticoagulant requirement in the aortic position. Second, a potential alternative to vitamin K-antagonist treatment, rivaroxaban, has shown encouraging results in small-scale trials and is currently being tested in a large randomized clinical trial. Lastly, an innovative mechanical valve that eliminates the need for anticoagulant therapy is under development. We attempted to review the current literature on the subject with special emphasis on the role of mechanical valves in the current era and discuss alternatives and future innovations. Full article
(This article belongs to the Special Issue Personalized Therapy and Clinical Outcome for Heart Valves)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop